Company intelligence / Profile preview
NeuExcell Therapeutics
King of Prussia, Pennsylvania, USAneuexcell.com ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Phase 1
01
Overview
NeuExcell has demonstrated proof-of-concept in rodents and non-human primates for its ATN platform. The company has robust preclinical data in three lead indications—glioblastoma, stroke, and Alzheimer's disease—and has initiated a first-in-human clinical trial for glioblastoma. The approach uses AAV vectors to deliver neural transcription factors that convert glial cells into functional neurons at the site of injury or degeneration.
- Therapeutic areas
- OncologyOphthalmologyNeurology
- Modalities
- Gene therapy (AAV-based)In vivo cell reprogramming (astrocyte-to-neuron conversion)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on NeuExcell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuExcell Therapeutics.